SJC28, CRP and change in TGSS in patients who attained normal CRP (CRP≤0.3 mg/dl) at 1 year or not. Data are shown as mean±SD for the three treatment arms. p Values denote differences among treatment groups (Kruskal–Wallis test)
| CRP≤0.3 mg/dl | CRP>0.3 mg/dl | |||||||
|---|---|---|---|---|---|---|---|---|
| Treatment | n | SJC28 | CRP | ΔTGSS | n | SJC28 | CRP | ΔTGSS |
| Placebo | 19 | 2.8±2.9 | 0.15±0.08 | 0.3±0.6 | 98 | 4.7±5.0 | 1.6±1.8 | 1.0±2.1 |
| TCZ 4 | 81 | 3.1±3.8 | 0.12±0.09 | 0.4±1.2 | 116 | 3.4±4.0 | 1.5±1.9 | 0.2±0.8 |
| TCZ 8 | 199 | 3.3±3.9 | 0.05±0.05 | 0.3±1.0 | 18 | 3.0±3.6 | 1.3±1.4 | 0.3±0.9 |
| p Value | 0.979 | 0.0001 | 0.449 | 0.069 | 0.471 | 0.015 | ||
CRP, C-reactive protein; SJC28, swollen joint count 28; TGSS, Genant-modified total Sharp score; TJC28, tender joint count 28, TCZ, tocilkizumab.